Every 424B that Acurx Pharmaceuticals, Inc. (ACXP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ACXP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACXP filings page.
Acurx Pharmaceuticals is registering up to 1,300,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC. These are Purchase Shares reserved under a Purchase Agreement dated May 8, 2025 and covered by a registration rights agreement. The company will not receive proceeds from resales by Lincoln Park under this prospectus; however, Acurx may sell additional shares to Lincoln Park under the Purchase Agreement for up to $4.7 million in aggregate gross proceeds remaining available to the company, subject to the Purchase Agreement terms, the Beneficial Ownership Cap, and our decision to direct purchases.
The registration covers shares that are freely tradable when issued and may be resold in various methods described in the Plan of Distribution. The arrangement follows prior registrations that have already resulted in $7.3 million of gross proceeds to Acurx from Lincoln Park purchases.
Acurx Pharmaceuticals, Inc. is registering 1,650,170 shares of common stock issuable upon exercise of series H warrants.
The prospectus states the warrants have an exercise price of $2.78 per share, are immediately exercisable and expire twenty-four months following the effective date of the registration statement. The selling stockholders will receive all sale proceeds; the company will receive proceeds only to the extent the warrants are exercised for cash.
Acurx Pharmaceuticals, Inc. is offering 816,068 shares of common stock and pre-funded warrants to purchase up to 9,017 shares of common stock to certain investors at $3.03 per share and $3.029 per pre-funded warrant, respectively. The pre-funded warrants have an exercise price of $0.001 and are immediately exercisable.
The offering assumes full exercise of the pre-funded warrants and would result in approximately 3,680,110 shares outstanding immediately following the offering (as presented). Net proceeds to the company are expected to be approximately $2.2 million, which Acurx intends to use for working capital and general corporate purposes.
Acurx Pharmaceuticals, Inc. is registering up to 750,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC under an existing purchase agreement. These shares may be issued to Lincoln Park over a 24‑month period, with Lincoln Park then selling them into the market.
Acurx will not receive proceeds from Lincoln Park’s resales, but may receive up to $7.6 million in aggregate gross proceeds from future sales of stock directly to Lincoln Park under the $12.0 million purchase agreement. As of January 30, 2026, Acurx had 2,546,717 shares outstanding, and operates as a late‑stage biopharmaceutical company developing Gram‑positive‑targeted antibiotics, including for C. difficile and MRSA.
Acurx Pharmaceuticals filed a resale prospectus for up to 585,000 shares of common stock to be sold from time to time by Lincoln Park Capital under an existing purchase agreement. The company is not selling any securities in this prospectus and will not receive proceeds from sales by the selling stockholder.
Under the Purchase Agreement, Acurx may sell additional shares to Lincoln Park at its discretion, from which the company may receive up to $9.0 million in aggregate gross proceeds (in addition to $3.0 million previously received), subject to terms and conditions. The selling stockholder is deemed an underwriter, and Acurx will cover registration expenses other than brokerage fees.
A 1-for-20 reverse stock split became effective on August 4, 2025. As of October 14, 2025, 2,081,323 shares were outstanding. If all 585,000 shares registered here were issued and outstanding as of that date, they would represent approximately 22% of total shares outstanding. A 4.99% Beneficial Ownership Cap applies to Lincoln Park, which may be increased to 9.99% upon notice and after 61 days.